Marlow, UK – 30 March 2022 – Tetris Pharma, a specialty pharmaceutical company distributing niche hospital and injectable prescription products across Europe, has entered into an agreement for storage and distribution services with Brocacef.
Tetris’s lead product, a prefilled glucagon pen, will be stored post-packaging at Brocacef’s facility in the Netherlands, and then released for European markets. Brocacef has a long heritage of 200 years, operating as a pre-wholesaler and wholesaler with the capability to distribute from the Netherlands across Europe. Brocacef is part of the PHOENIX group, a leading healthcare provider, which has 161 distribution centres in 26 countries. Tetris is working with the group to implement tailored solutions where required to ensure availability of products for patients.
Dr Shafiq Choudhary, CEO of Tetris, commented: “We are pleased to be partnering with Brocacef. The Company’s extensive network, which spans 26 countries, positions us well to supply products to patients throughout our key target markets. This is the second supply and distribution agreement we’ve announced this quarter, growing our pan-European platform for the delivery of niche prescription products by appointing experienced and trusted partners.”
Tetris’s current pipeline includes 10 license and supply agreements with large pharma. The Company plans to grow this by adding two-to-three new in-licensed or acquired products per year.
- ENDS -
About Tetris Pharma
Tetris Pharma is a British specialty pharmaceutical company building a marketing and distribution platform across Europe for ‘niche’ injectable and hospital-based prescription products in areas of unmet medical need.
The management team has in-depth market expertise, with a proven track record of acquiring, in-licensing, and marketing products from global pharma companies across a range of therapeutic areas. Tetris currently has 10 license and supply agreements with large pharma and plans to add two-to-three new in-licensed or acquired products per year to its pipeline.
Tetris Pharma is working with expert development, manufacturing, and distribution partners in the UK and mainland Europe, initially to bring to market its lead product, a pre-filled glucagon pen to treat severe episodes of hypoglycaemia for people living with diabetes.
The privately held Company, which has offices in the UK and the Netherlands, was founded in 2020. To-date, Tetris Pharma shareholders have invested circa £1M with a view to extending the platform across Europe through external investments.
For more information, please visit the Company website at: www.tetrispharma.com, or follow us on Twitter or LinkedIn.
Brocacef consists of a group of companies that are committed to people's health on a daily basis. The Brocacef brand serves a wide variety of healthcare providers in the business market. From pharmacies and dispensing general practitioners to hospitals, care, and nursing homes. Brocacef has a fully-stocked wholesaler for these customers, from which pharmaceutical products are delivered day and night. In addition, Brocacef offers a wide range of services that enable our business customer to optimize business operations to spend more time with the patient.
For more information, see: www.brocacef.nl